Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report
Ophthalmology Science · 2026-04 · 6 (4) · 101087
DOI: 10.1016/j.xops.2026.101087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2026-04. Verfasst von Jan Spindler und 21 weiteren Autor:innen. Beteiligte Einrichtung: Berner Augenklinik and Swiss Eye Institute, Bern, Switzerland. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Novartis.
Abstract (Originalsprache)
Purpose
To evaluate the effectiveness and safety of intravitreal aflibercept 8 mg (Afl 8) for the therapy of treatment-naïve and pretreated diabetic macular edema (DME) in a clinical routine setting.
Design
A multicenter, retrospective cohort study of consecutive DME patients treated with Afl 8 over 12 months. Subjects: One hundred fifty-six eyes (124 patients) with DME, including 42 (26.9%) treatment-naïve and 114 (73.1%) pretreated eyes receiving Afl 8 for 1 year.
Methods
Data from electronic medical records were collected retrospectively at 5 predefined time points. The primary outcomes were the mean changes in corrected visual acuity (VA), center-point retinal thickness (CRT), central subfield thickness (CST), treatment intervals, and adverse events (AEs). Secondary outcomes included the number of injections, persistent fluid, and treatment adherence. These parameters were recorded from the beginning of anti-VEGF treatment until switching occurred in pretreated eyes. Main Outcome Measures: Mean change in VA, CRT, CST, treatment intervals, and AEs.
Results
In treatment-naïve eyes, VA improved from 72.9 ± 10.7 ETDRS letters at baseline to 77.7 ± 9.7 (P = 0.006); and from 73.9 ± 11.2 to 75.4 ± 10.1 ETDRS letters (P = 0.094) in pretreated eyes. Central subfield thickness decreased in both groups (naïve: 448.9 ± 154.3 μm to 320.0 ± 80.1 μm, P < 0.001; pretreated: 336.6 ± 90.5 μm to 310.2 ± 69.9 μm, P = 0.047). After 12 months, 38.1% of naïve eyes and 27.2% of pretreated eyes were free of retinal fluid in the central 1 mm. In treatment-naïve eyes, the mean treatment interval was 15.3 ± 12.0 weeks at 12 months. In pretreated eyes, the interval increased from 7.6 ± 3.7 weeks at the time of switching to 13.0 ± 9.0 weeks (P < 0.001). Two eyes (4.8%) in the naïve group and 16 eyes (14%) in the switcher group were switched away within the first year due to insufficient response to Afl 8 therapy. No AEs were reported in the treatment-naïve group. In the pretreated group, 3 cases of noninfectious intraocular inflammation (IOI; 1.9%; 1 recurrent), 2 instances of acute intraocular pressure rise, and 1 vitreous hemorrhage were reported.
Conclusions
Afl 8 offers a promising approach to reducing the treatment burden in DME. It enables extended dosing intervals without compromising efficacy and safety, especially in refractory eyes. However, a possibly increased rate of mild IOI has been observed. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Berner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
- Department of Ophthalmology, Kantonsspital St. Gallen, Switzerland.
- Augenärzte Praxisgemeinschaft Gutblick AG, Pfaeffikon, Switzerland.
- Vista Augenklinik Binningen, Binningen, Switzerland.
- Department of Ophthalmology, University Hospital Zuerich, University of Zuerich, Switzerland.
- Ente Ospedaliero Cantonale (EOC), Ophthalmology Clinic, and Institute of Clinical Neurosciences of Southern Switzerland (INSI) Lugano, Switzerland.
Förderung
- Bayer
- Novartis
Zitieren
APA
Spindler, J., Artemiev, D., Pfister, I. B., Schild, C., Tillmann, A., Heck, K., Gabathuler, F., Ruscitti, L., Spitznagel, T., Kitsos-Kalyvianakis, K., Munk, M. R., Hatz, K., Zweifel, S. A., Grimaldi, G., Somfai, G. M., Ambresin, A., Weinberger, A., Eandi, C. M., Feltgen, N., …, & Garweg, J. G. (2026). Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report. Ophthalmology Science, 6(4), 101087. https://doi.org/10.1016/j.xops.2026.101087
Vancouver
Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, et al. Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report. Ophthalmology Science. 2026;6(4):101087. doi:10.1016/j.xops.2026.101087
BibTeX
@article{Spindler2026,
author = {Spindler, Jan and Artemiev, Dmitri and Pfister, Isabel B and Schild, Christin and Tillmann, Anne and Heck, Katharina and Gabathuler, Felix and Ruscitti, Ludovico and Spitznagel, Tahm and Kitsos-Kalyvianakis, Konstantinos and Munk, Marion R and Hatz, Katja and Zweifel, Sandrine A and Grimaldi, Gabriela and Somfai, Gábor Márk and Ambresin, Aude and Weinberger, Andreas and Eandi, Chiara M and Feltgen, Nicolas and Kitay, Alice and Ebneter, Andreas and Garweg, Justus G},
title = {Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report},
journal = {Ophthalmology Science},
year = {2026},
volume = {6},
number = {4},
pages = {101087},
doi = {10.1016/j.xops.2026.101087}
}
EUVIMED